Operating Profit Margin
since 2005
Calculation
Celgene Corp., operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Operating income (loss)1 | ÷ | Net product sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 34.01% | = | 100 | × | 5,191) | ÷ | 15,265) |
| Dec 31, 2017 | 36.28% | = | 100 | × | 4,707) | ÷ | 12,973) |
| Dec 31, 2016 | 28.31% | = | 100 | × | 3,167) | ÷ | 11,185) |
| Dec 31, 2015 | 24.61% | = | 100 | × | 2,255) | ÷ | 9,161) |
| Dec 31, 2014 | 33.30% | = | 100 | × | 2,519) | ÷ | 7,564) |
| Dec 31, 2013 | 28.43% | = | 100 | × | 1,809) | ÷ | 6,362) |
| Dec 31, 2012 | 32.43% | = | 100 | × | 1,746) | ÷ | 5,386) |
| Dec 31, 2011 | 30.70% | = | 100 | × | 1,443) | ÷ | 4,700) |
| Dec 31, 2010 | 28.21% | = | 100 | × | 990) | ÷ | 3,508) |
| Dec 31, 2009 | 32.78% | = | 100 | × | 842) | ÷ | 2,567) |
| Dec 31, 2008 | -68.50% | = | 100 | × | (1,464) | ÷ | 2,138) |
| Dec 31, 2007 | 32.69% | = | 100 | × | 425) | ÷ | 1,300) |
| Dec 31, 2006 | 21.52% | = | 100 | × | 175) | ÷ | 812) |
| Dec 31, 2005 | 18.76% | = | 100 | × | 84) | ÷ | 446) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The financial performance from 2005 to 2018 is characterized by consistent revenue expansion and a generally strong operating profile, despite a period of extreme volatility in 2008.
- Revenue Growth Trends
- Net product sales demonstrate a sustained and aggressive upward trajectory, increasing from 446 million US dollars in 2005 to 15,265 million US dollars by 2018. This consistent growth indicates a significant expansion in market reach and product demand over the thirteen-year period.
- Operating Income Volatility
- Operating income grew steadily during the initial period before experiencing a severe contraction in 2008, resulting in a loss of 1,464 million US dollars. A rapid recovery occurred in 2009, with operating income returning to a positive 842 million US dollars. Following this recovery, operating income entered a period of accelerated growth, peaking at 5,191 million US dollars in 2018.
- Operating Profit Margin Analysis
- The operating profit margin exhibited three distinct phases. The first phase (2005-2007) showed improvement, rising from 18.76% to 32.69%. The second phase was marked by the 2008 anomaly, where the margin plummeted to -68.50% before rebounding to 32.78% in 2009. The final phase (2009-2018) reflects relative stability and optimization, with margins typically fluctuating between 24% and 36%. The peak margin of 36.28% was achieved in 2017, indicating high operational efficiency relative to the scale of the business.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Comparison to Competitors
Celgene Corp., operating profit margin, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 34.01% | 19.49% | 45.55% | 17.11% | 37.83% | 37.77% | 15.53% | 20.84% |
| Dec 31, 2017 | 36.28% | 33.99% | 45.76% | 16.48% | 55.04% | 35.41% | 14.19% | 4.95% |
| Dec 31, 2016 | 28.31% | 36.60% | 44.74% | 16.29% | 58.87% | 27.38% | 13.40% | 0.58% |
| Dec 31, 2015 | 24.61% | 32.97% | 40.44% | 16.87% | 69.03% | 30.51% | 13.77% | -45.23% |
| Dec 31, 2014 | 33.30% | 17.09% | 32.03% | 17.23% | 62.37% | 29.74% | 14.82% | -119.30% |
| Dec 31, 2013 | 28.43% | 30.14% | 32.25% | 17.13% | 41.87% | 36.11% | 12.30% | -74.54% |
| Dec 31, 2012 | 32.43% | 31.65% | 33.52% | 17.33% | 42.67% | 33.20% | 11.85% | 0.15% |
| Dec 31, 2011 | 30.70% | — | 28.19% | 16.27% | 46.77% | -46.02% | 10.62% | 8.07% |
| Dec 31, 2010 | 28.21% | — | 37.82% | 16.41% | 53.62% | -21.23% | 11.72% | -485.51% |
| Dec 31, 2009 | 32.78% | — | 38.37% | 13.79% | 54.55% | -19.54% | 10.38% | -602.63% |
| Dec 31, 2008 | -68.50% | — | 35.50% | 14.72% | 52.68% | -37.67% | 11.71% | -263.65% |
| Dec 31, 2007 | 32.69% | — | 27.81% | 15.79% | 57.98% | -91.55% | 10.00% | -210.94% |
| Dec 31, 2006 | 21.52% | — | 27.71% | 15.82% | -29.32% | -169.68% | 6.38% | -105.86% |
| Dec 31, 2005 | 18.76% | — | 40.33% | 15.84% | 61.41% | -187.97% | 10.01% | -93.15% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).